x
|
Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934 for the Quarter Ended April 3,
2010
|
o
|
Transition
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
Delaware
|
04-2209186
|
(State
of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
81
Wyman Street
|
|
Waltham,
Massachusetts
|
02451
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Class
|
Outstanding
at April 3, 2010
|
|
Common
Stock, $1.00 par value
|
410,405,951
|
|
April
3,
|
December
31,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Assets
|
|
|
|||||
Current
Assets:
|
|
|
|||||
Cash and cash equivalents
|
$ | 1,431.7 | $ | 1,564.1 | |||
Short-term investments, at quoted market value (cost of $9.0 and
$7.7)
|
8.5 | 7.1 | |||||
Accounts receivable, less allowances of $46.1 and $47.2
|
1,493.8 | 1,409.6 | |||||
Inventories:
|
|||||||
Raw materials
|
269.3 | 262.8 | |||||
Work in process
|
121.4 | 115.5 | |||||
Finished goods
|
763.9 | 753.1 | |||||
Deferred tax assets
|
161.0 | 160.0 | |||||
Other current assets
|
279.0 | 258.7 | |||||
|
|||||||
|
4,528.6 | 4,530.9 | |||||
|
|||||||
Property,
Plant and Equipment, at Cost
|
2,078.5 | 2,071.8 | |||||
Less: Accumulated depreciation and amortization
|
(766.2 | ) | (738.4 | ) | |||
|
|||||||
|
1,312.3 | 1,333.4 | |||||
|
|||||||
Acquisition-related
Intangible Assets, net of Accumulated Amortization of
$2,204.1 and $2,074.1
|
6,238.6 | 6,337.0 | |||||
|
|||||||
Other
Assets
|
436.4 | 440.8 | |||||
|
|||||||
Goodwill
|
9,108.7 | 8,982.9 | |||||
|
|||||||
|
$ | 21,624.6 | $ | 21,625.0 |
|
April
3,
|
December
31,
|
|||||
(In
millions except share amounts)
|
2010
|
2009
|
|||||
|
|
|
|||||
Liabilities
and Shareholders' Equity
|
|
|
|||||
Current
Liabilities:
|
|
|
|||||
Short-term obligations and current maturities of long-term
obligations
|
$ | 148.8 | $ | 117.5 | |||
Accounts payable
|
596.1 | 533.6 | |||||
Accrued payroll and employee benefits
|
246.1 | 286.0 | |||||
Accrued income taxes
|
63.6 | 28.4 | |||||
Deferred revenue
|
167.8 | 139.8 | |||||
Other accrued expenses
|
553.3 | 534.0 | |||||
|
|||||||
|
1,775.7 | 1,639.3 | |||||
|
|||||||
Deferred
Income Taxes
|
1,897.6 | 1,933.8 | |||||
|
|||||||
Other
Long-term Liabilities
|
541.0 | 555.1 | |||||
|
|||||||
Long-term
Obligations
|
1,923.2 | 2,064.0 | |||||
|
|||||||
|
|||||||
Incremental
Convertible Debt Obligation
|
7.1 | 1.9 | |||||
|
|||||||
Shareholders'
Equity:
|
|||||||
Preferred stock, $100 par value, 50,000 shares authorized; none
issued
|
|||||||
Common stock, $1 par value, 1,200,000,000 shares authorized; 425,105,836
and 423,875,260 shares issued
|
425.1 | 423.9 | |||||
Capital in excess of par value
|
11,102.2 | 11,140.7 | |||||
Retained earnings
|
4,583.1 | 4,350.8 | |||||
Treasury stock at cost, 14,699,885 and 14,564,637 shares
|
(583.1 | ) | (576.5 | ) | |||
Accumulated other comprehensive items
|
(47.3 | ) | 92.0 | ||||
|
|||||||
|
15,480.0 | 15,430.9 | |||||
|
|||||||
|
$ | 21,624.6 | $ | 21,625.0 |
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions except per share amounts)
|
2010
|
2009
|
|||||
|
|
|
|||||
Revenues
|
|
|
|||||
Product revenues
|
$ | 2,281.0 | $ | 1,898.6 | |||
Service revenues
|
394.1 | 356.5 | |||||
|
|||||||
|
2,675.1 | 2,255.1 | |||||
|
|||||||
Costs
and Operating Expenses:
|
|||||||
Cost of product revenues
|
1,350.4 | 1,159.7 | |||||
Cost of service revenues
|
228.4 | 208.5 | |||||
Selling, general and administrative expenses
|
719.1 | 625.0 | |||||
Research and development expenses
|
66.8 | 58.2 | |||||
Restructuring and other costs, net
|
17.4 | 13.6 | |||||
|
|||||||
|
2,382.1 | 2,065.0 | |||||
|
|||||||
Operating
Income
|
293.0 | 190.1 | |||||
Other
Expense, Net
|
(24.9 | ) | (22.9 | ) | |||
|
|||||||
Income
from Continuing Operations Before Provision for Income
Taxes
|
268.1 | 167.2 | |||||
Provision
for Income Taxes
|
(38.3 | ) | (18.3 | ) | |||
|
|||||||
Income
from Continuing Operations
|
229.8 | 148.9 | |||||
Gain
on Disposal of Discontinued Operations, Net (net of income
tax provision
of $1.5 in 2010)
|
2.5 | — | |||||
|
|||||||
Net
Income
|
$ | 232.3 | $ | 148.9 | |||
|
|||||||
Earnings
per Share from Continuing Operations
|
|||||||
Basic
|
$ | .56 | $ | .36 | |||
Diluted
|
$ | .55 | $ | .35 | |||
|
|||||||
Earnings
per Share
|
|||||||
Basic
|
$ | .57 | $ | .36 | |||
Diluted
|
$ | .56 | $ | .35 | |||
|
|||||||
Weighted
Average Shares
|
|||||||
Basic
|
409.6 | 417.7 | |||||
Diluted
|
418.2 | 425.3 |
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Operating
Activities
|
|
|
|||||
Net Income
|
$ | 232.3 | $ | 148.9 | |||
Gain on disposal of discontinued operations
|
(2.5 | ) | — | ||||
|
|||||||
Income from continuing operations
|
229.8 | 148.9 | |||||
|
|||||||
Adjustments to reconcile income from continuing operations to
net cash provided by operating activities:
|
|||||||
Depreciation and amortization
|
199.7 | 190.3 | |||||
Change in deferred income taxes
|
(45.8 | ) | (56.7 | ) | |||
Non-cash stock-based compensation
|
19.1 | 15.2 | |||||
Non-cash interest expense on convertible debt
|
3.4 | 5.6 | |||||
Tax benefits from stock-based compensation awards
|
(4.8 | ) | (0.6 | ) | |||
Other non-cash expenses, net
|
16.9 | 11.1 | |||||
Changes in assets and liabilities, excluding the effects of acquisitions
and dispositions:
|
|||||||
Accounts receivable
|
(102.1 | ) | 29.0 | ||||
Inventories
|
(34.9 | ) | (11.8 | ) | |||
Other assets
|
(23.0 | ) | 28.9 | ||||
Accounts payable
|
74.0 | 81.5 | |||||
Other liabilities
|
15.7 | (76.9 | ) | ||||
Contributions to retirement plans
|
(4.9 | ) | (5.6 | ) | |||
|
|||||||
Net cash provided by continuing operations
|
343.1 | 358.9 | |||||
Net cash used in discontinued operations
|
— | (0.2 | ) | ||||
|
|||||||
Net cash provided by operating activities
|
343.1 | 358.7 | |||||
|
|||||||
Investing
Activities
|
|||||||
Acquisitions, net of cash acquired
|
(229.1 | ) | (18.3 | ) | |||
Purchase of property, plant and equipment
|
(50.6 | ) | (51.2 | ) | |||
Proceeds from sale of property, plant and equipment
|
1.0 | 3.4 | |||||
Proceeds from sale of available-for-sale investments
|
0.2 | — | |||||
Proceeds from sale of businesses, net of cash divested
|
— | 2.3 | |||||
Decrease (increase) in other assets
|
0.6 | (1.9 | ) | ||||
|
|||||||
Net cash used in investing activities
|
$ | (277.9 | ) | $ | (65.7 | ) |
Three Months Ended | |||||||
(In millions) |
April
3,
2010
|
March
28,
2009
|
|||||
|
|
|
|||||
Financing
Activities
|
|
|
|||||
Increase (decrease) in short-term notes payable
|
$ | (0.3 | ) | $ | 0.6 | ||
Net proceeds from issuance of company common stock
|
26.8 | 5.2 | |||||
Tax benefits from stock-based compensation awards
|
4.8 | 0.6 | |||||
Settlement of convertible debt
|
(206.9 | ) | — | ||||
Borrowings (redemption and repayment) of long-term
obligations
|
(2.5 | ) | 3.4 | ||||
|
|||||||
Net cash provided by (used in) financing activities
|
(178.1 | ) | 9.8 | ||||
|
|||||||
Exchange
Rate Effect on Cash of Continuing Operations
|
(19.5 | ) | (22.2 | ) | |||
|
|||||||
Increase
(Decrease) in Cash and Cash Equivalents
|
(132.4 | ) | 280.6 | ||||
Cash
and Cash Equivalents at Beginning of Period
|
1,564.1 | 1,280.5 | |||||
|
|||||||
Cash
and Cash Equivalents at End of Period
|
$ | 1,431.7 | $ | 1,561.1 | |||
|
|||||||
|
|||||||
Supplemental
Cash Flow Information
|
|||||||
Fair value of assets of acquired businesses
|
$ | 330.5 | $ | 10.4 | |||
Cash paid for acquired businesses
|
(244.6 | ) | (7.7 | ) | |||
|
|||||||
Fair value of liabilities assumed of acquired businesses
|
$ | 85.9 | $ | 2.7 | |||
|
|||||||
Issuance of stock upon vesting of restricted stock units
|
$ | 14.9 | $ | 6.6 |
(In
millions)
|
Ahura
Scientific
|
Finnzymes
|
Other
|
Total
|
|||||||||
|
|
|
|
|
|||||||||
Purchase
Price
|
|
|
|
|
|||||||||
Cash paid
|
$ | 164.3 | $ | 59.3 | $ | 21.0 | $ | 244.6 | |||||
Debt assumed
|
0.6 | — | — | 0.6 | |||||||||
Fair value of contingent consideration
|
19.6 | — | 2.1 | 21.7 | |||||||||
Cash acquired
|
(17.8 | ) | (0.7 | ) | — | (18.5 | ) | ||||||
|
|||||||||||||
|
$ | 166.7 | $ | 58.6 | $ | 23.1 | $ | 248.4 | |||||
|
|||||||||||||
Allocation
|
|||||||||||||
Current assets
|
$ | 21.5 | $ | 6.6 | $ | 0.6 | $ | 28.7 | |||||
Property, plant and equipment
|
3.3 | 3.4 | — | 6.7 | |||||||||
Intangible assets:
|
|||||||||||||
Customer relationships
|
46.1 | 16.1 | 0.8 | 63.0 | |||||||||
Product technology
|
30.3 | 18.6 | 8.2 | 57.1 | |||||||||
In-process research and development
|
— | — | 2.9 | 2.9 | |||||||||
Tradenames and other
|
0.4 | 0.1 | 0.1 | 0.6 | |||||||||
Goodwill
|
110.7 | 26.6 | 15.6 | 152.9 | |||||||||
Other assets
|
0.1 | — | — | 0.1 | |||||||||
Liabilities assumed
|
(45.7 | ) | (12.8 | ) | (5.1 | ) | (63.6 | ) | |||||
|
|||||||||||||
|
$ | 166.7 | $ | 58.6 | $ | 23.1 | $ | 248.4 |
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Revenues
|
|
|
|||||
Analytical Technologies
|
$ | 1,107.0 | $ | 938.8 | |||
Laboratory Products and Services
|
1,695.2 | 1,423.0 | |||||
Eliminations
|
(127.1 | ) | (106.7 | ) | |||
|
|||||||
Consolidated revenues
|
2,675.1 | 2,255.1 | |||||
|
|||||||
Segment
Income
|
|||||||
Analytical Technologies (a)
|
232.4 | 173.5 | |||||
Laboratory Products and Services (a)
|
235.3 | 175.5 | |||||
|
|||||||
Subtotal reportable segments (a)
|
467.7 | 349.0 | |||||
|
|||||||
Cost of revenues charges
|
(5.1 | ) | — | ||||
Selling, general and administrative charges, net
|
(1.1 | ) | — | ||||
Restructuring and other costs, net
|
(17.4 | ) | (13.6 | ) | |||
Amortization of acquisition-related intangible assets
|
(151.1 | ) | (145.3 | ) | |||
|
|||||||
Consolidated operating income
|
293.0 | 190.1 | |||||
Other expense, net (b)
|
(24.9 | ) | (22.9 | ) | |||
|
|||||||
Income from continuing operations before provision for income
taxes
|
$ | 268.1 | $ | 167.2 | |||
|
|||||||
Depreciation
|
|||||||
Analytical Technologies
|
$ | 22.0 | $ | 20.3 | |||
Laboratory Products and Services
|
26.6 | 24.7 | |||||
|
|||||||
Consolidated depreciation
|
$ | 48.6 | $ | 45.0 |
(a)
|
Represents
operating income before certain charges to cost of revenues and selling,
general and administrative expenses; restructuring and other costs, net;
and amortization
of acquisition-related intangibles.
|
(b)
|
The
company does not allocate other expense, net to its
segments.
|
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Interest
Income
|
$ | 2.4 | $ | 5.3 | |||
Interest
Expense
|
(22.3 | ) | (30.2 | ) | |||
Other
Items, Net
|
(5.0 | ) | 2.0 | ||||
|
|||||||
|
$ | (24.9 | ) | $ | (22.9 | ) |
Three Months Ended | |||||||
(In millions) |
April
3,
2010
|
March
28,
2009
|
|||||
|
|
|
|||||
Stock
Option Awards
|
$ | 11.6 | $ | 10.1 | |||
Restricted
share/Unit Awards
|
7.5 | 5.1 | |||||
|
|||||||
Total
Stock-based Compensation Expense
|
$ | 19.1 | $ | 15.2 |
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Cost
of Revenues
|
$ | 1.4 | $ | 1.5 | |||
Selling,
General and Administrative Expenses
|
17.3 | 13.2 | |||||
Research
and Development Expenses
|
0.4 | 0.5 | |||||
|
|||||||
Total
Stock-based Compensation Expense
|
$ | 19.1 | $ | 15.2 |
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Service
Cost
|
$ | 2.8 | $ | 2.5 | |||
Interest
Cost on Benefit Obligation
|
13.2 | 12.0 | |||||
Expected
Return on Plan Assets
|
(13.8 | ) | (12.3 | ) | |||
Amortization
of Net Loss
|
0.5 | 0.3 | |||||
Amortization
of Prior Service Benefit
|
— | 0.1 | |||||
Special
Termination Benefits
|
— | 0.2 | |||||
|
|||||||
Net
Periodic Benefit Cost
|
$ | 2.7 | $ | 2.8 |
Three Months Ended | |||||||
(In millions) |
April
3,
2010
|
March
28,
2009
|
|||||
|
|
|
|||||
Service
Cost
|
$ | 0.1 | $ | 0.1 | |||
Interest
Cost on Benefit Obligation
|
0.5 | 0.4 | |||||
Amortization
of Net Gain
|
(0.1 | ) | — | ||||
|
|||||||
Net
Periodic Benefit Cost
|
$ | 0.5 | $ | 0.5 |
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions except per share amounts)
|
2010
|
2009
|
|||||
|
|
|
|||||
Income
from Continuing Operations
|
$ | 229.8 | $ | 148.9 | |||
Gain
on Disposal of Discontinued Operations, Net
|
2.5 | — | |||||
|
|||||||
Net
Income
|
232.3 | 148.9 | |||||
|
|||||||
Income
Allocable to Participating Securities
|
— | (0.2 | ) | ||||
|
|||||||
Net
Income for Earnings per Share
|
$ | 232.3 | $ | 148.7 | |||
|
|||||||
Basic
Weighted Average Shares
|
409.6 | 417.7 | |||||
Effect
of:
|
|||||||
Convertible debentures
|
5.4 | 6.4 | |||||
Stock options, restricted stock/units and warrants
|
3.2 | 1.2 | |||||
|
|||||||
Diluted
Weighted Average Shares
|
418.2 | 425.3 | |||||
|
|||||||
Basic
Earnings per Share:
|
|||||||
Continuing operations
|
$ | .56 | $ | .36 | |||
Discontinued operations
|
.01 | — | |||||
|
|||||||
|
$ | .57 | $ | .36 | |||
|
|||||||
Diluted
Earnings per Share:
|
|||||||
Continuing operations
|
$ | .55 | $ | .35 | |||
Discontinued operations
|
.01 | — | |||||
|
|||||||
|
$ | .56 | $ | .35 |
|
April
3,
|
December
31,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Principal
Amount of Convertible Debt
|
$ | 546.9 | $ | 668.8 | |||
Unamortized
Discount
|
7.1 | 10.9 | |||||
Net
Carrying Amount
|
539.8 | 657.9 | |||||
Incremental
Convertible Debt Obligation (Temporary Equity)
|
7.1 | 1.9 | |||||
Capital
in Excess of Par Value
|
20.1 | 30.7 |
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Contractual
Coupon Interest
|
$ | 2.9 | $ | 5.0 | |||
Amortization
of Discount on Convertible Debt
|
3.4 | 5.6 | |||||
|
|||||||
Interest
Expense
|
$ | 6.3 | $ | 10.6 | |||
|
|||||||
Effective
Interest Rate
|
4.0% | 4.5% |
|
April
3,
|
Quoted
Prices
in
Active
Markets
|
Significant
Other
Observable
Inputs
|
Significant
Unobservable Inputs
|
|||||||||
(In
millions)
|
2010
|
(Level
1)
|
(Level
2)
|
(Level
3)
|
|||||||||
|
|
|
|
|
|||||||||
Assets
|
|
|
|
|
|||||||||
Cash
equivalents
|
$ | 833.5 | $ | 833.5 | $ | — | $ | — | |||||
Investments in mutual funds, unit trusts and
other similar instruments
|
33.9 | 33.9 | — | — | |||||||||
Insurance contracts
|
32.3 | — | 32.3 | — | |||||||||
Auction rate securities
|
5.2 | — | — | 5.2 | |||||||||
Derivative contracts
|
1.7 | — | 1.7 | — | |||||||||
|
|||||||||||||
Total Assets
|
$ | 906.6 | $ | 867.4 | $ | 34.0 | $ | 5.2 | |||||
|
|||||||||||||
Liabilities
|
|||||||||||||
Derivative contracts
|
$ | 2.1 | $ | — | $ | 2.1 | $ | — | |||||
|
|||||||||||||
Total Liabilities
|
$ | 2.1 | $ | — | $ | 2.1 | $ | — |
|
December
31,
|
Quoted
Prices
in
Active
Markets
|
Significant
Other
Observable
Inputs
|
Significant
Unobservable Inputs
|
|||||||||
(In
millions)
|
2009
|
(Level
1)
|
(Level
2)
|
(Level
3)
|
|||||||||
|
|
|
|
|
|||||||||
Assets
|
|
|
|
|
|||||||||
Cash equivalents
|
$ | 1,081.7 | $ | 1,081.7 | $ | — | $ | — | |||||
Investments in mutual funds, unit trusts and
other similar instruments
|
32.9 | 32.9 | — | — | |||||||||
Insurance contracts
|
31.9 | — | 31.9 | — | |||||||||
Auction rate securities
|
5.4 | — | — | 5.4 | |||||||||
Derivative contracts
|
4.5 | — | 4.5 | — | |||||||||
|
|||||||||||||
Total Assets
|
$ | 1,156.4 | $ | 1,114.6 | $ | 36.4 | $ | 5.4 | |||||
|
|||||||||||||
Liabilities
|
|||||||||||||
Derivative contracts
|
$ | 10.3 | $ | — | $ | 10.3 | $ | — | |||||
|
|||||||||||||
Total Liabilities
|
$ | 10.3 | $ | — | $ | 10.3 | $ | — |
|
|
Three
Months Ended
|
||||
|
|
April
3,
|
|
March
28,
|
||
(In
millions)
|
|
2010
|
|
2009
|
||
|
|
|
|
|
|
|
Beginning
Balance
|
|
$
|
5.4
|
|
$
|
5.7
|
Sale
of securities
|
|
|
(0.2)
|
|
|
—
|
Total
unrealized gains (losses) included in other comprehensive
income
|
|
|
—
|
|
|
0.6
|
|
|
|
|
|
|
|
Ending
Balance
|
|
$
|
5.2
|
|
$
|
6.3
|
|
Fair
Value – Assets
|
Fair
Value – Liabilities
|
|||||||||||
|
April
3,
|
December
31,
|
April
3,
|
December
31,
|
|||||||||
(In
millions)
|
2010
|
2009
|
2010
|
2009
|
|||||||||
|
|
|
|
|
|||||||||
Derivatives
Designated as Hedging Instruments
|
|
|
|
|
|||||||||
Interest rate swaps (a)
|
$ | 1.5 | $ | — | $ | — | $ | 9.5 | |||||
Derivatives
Not Designated as Hedging Instruments
|
|||||||||||||
Foreign currency exchange contracts (b)
|
0.2 | 4.5 | 2.1 | 0.8 | |||||||||
|
|||||||||||||
Total derivatives
|
$ | 1.7 | $ | 4.5 | $ | 2.1 | $ | 10.3 |
Gain Recognized | |||||||
Three Months Ended | |||||||
(In millions) |
April
3,
2010
|
March
28,
2009
|
|||||
|
|
|
|||||
Derivatives
Designated as Fair Value Hedges
|
|
|
|||||
Interest rate contracts
|
$ | 3.4 | $ | — | |||
Derivatives
Not Designated as Fair Value Hedges
|
|||||||
Foreign currency exchange contracts
|
17.9 | 10.9 |
|
April
3, 2010
|
December
31, 2009
|
|||||||||||
|
Carrying
|
Fair
|
Carrying
|
Fair
|
|||||||||
(In
millions)
|
Value
|
Value
|
Value
|
Value
|
|||||||||
|
|
|
|
|
|||||||||
Notes
Receivable
|
$ | 5.7 | $ | 5.7 | $ | 6.8 | $ | 6.8 | |||||
|
|||||||||||||
Debt
Obligations:
|
|||||||||||||
Convertible obligations
|
539.8 | 826.7 | 657.9 | 992.0 | |||||||||
Senior notes
|
1,000.7 | 1,012.0 | 989.6 | 1,016.1 | |||||||||
Senior subordinated notes
|
500.0 | 518.8 | 500.0 | 520.1 | |||||||||
Other
|
31.5 | 31.5 | 34.0 | 34.0 | |||||||||
|
|||||||||||||
|
$ | 2,072.0 | $ | 2,389.0 | $ | 2,181.5 | $ | 2,562.2 |
|
Three
Months Ended
|
||||||
|
April
3,
|
March
28,
|
|||||
(In
millions)
|
2010
|
2009
|
|||||
|
|
|
|||||
Beginning
Balance
|
$ | 45.2 | $ | 44.1 | |||
Provision charged to income
|
10.8 | 7.5 | |||||
Usage
|
(10.1 | ) | (10.4 | ) | |||
Acquisitions
|
0.2 | — | |||||
Adjustments to previously provided warranties, net
|
0.4 | 0.5 | |||||
Other, net (a)
|
(1.0 | ) | (1.0 | ) | |||
|
|||||||
Ending
Balance
|
$ | 45.5 | $ | 40.7 |
(In
millions)
|
|
Analytical
Technologies
|
|
Laboratory
Products and Services
|
|
Corporate
|
|
Total
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
of Revenues
|
|
$
|
3.9
|
|
$
|
1.2
|
|
$
|
—
|
|
$
|
5.1
|
Selling,
General and Administrative Expenses
|
|
|
1.1
|
|
|
—
|
|
|
—
|
|
|
1.1
|
Restructuring
and Other Costs, Net
|
|
|
8.0
|
|
|
9.3
|
|
|
0.1
|
|
|
17.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
13.0
|
|
$
|
10.5
|
|
$
|
0.1
|
|
$
|
23.6
|
(In
millions)
|
Severance
|
Employee
Retention (a)
|
Abandonment
of
Excess Facilities
|
Other
|
Total
|
|||||||||||
|
|
|
|
|
|
|||||||||||
Pre-2009
Restructuring Plans
|
|
|
|
|
|
|||||||||||
Balance
At December 31, 2009
|
$ | 2.5 | $ | — | $ | 4.3 | $ | 0.3 | $ | 7.1 | ||||||
Costs
incurred in 2010 (b)
|
— | — | 0.7 | 0.1 | 0.8 | |||||||||||
Payments
|
(0.4 | ) | — | (0.9 | ) | (0.4 | ) | (1.7 | ) | |||||||
Currency
translation
|
(0.1 | ) | — | — | — | (0.1 | ) | |||||||||
|
||||||||||||||||
Balance
At April 3, 2010
|
$ | 2.0 | $ | — | $ | 4.1 | $ | — | $ | 6.1 | ||||||
|
||||||||||||||||
2009
Restructuring Plans
|
||||||||||||||||
Balance
At December 31, 2009
|
$ | 21.0 | $ | 1.6 | $ | 2.3 | $ | 0.2 | $ | 25.1 | ||||||
Costs
incurred in 2010 (b)
|
3.5 | 1.2 | 1.1 | 1.2 | 7.0 | |||||||||||
Reserves
reversed
|
(0.9 | ) | (0.1 | ) | (0.1 | ) | — | (1.1 | ) | |||||||
Payments
|
(6.2 | ) | (0.8 | ) | (0.6 | ) | (1.1 | ) | (8.7 | ) | ||||||
Currency
translation
|
(1.0 | ) | — | — | — | (1.0 | ) | |||||||||
|
||||||||||||||||
Balance
At April 3, 2010
|
$ | 16.4 | $ | 1.9 | $ | 2.7 | $ | 0.3 | $ | 21.3 | ||||||
|
||||||||||||||||
2010
Restructuring Plans
|
||||||||||||||||
Costs
incurred in 2010 (b)
|
$ | 3.1 | $ | — | $ | 1.4 | $ | 0.4 | $ | 4.9 | ||||||
Payments
|
(1.0 | ) | — | (0.2 | ) | (0.4 | ) | (1.6 | ) | |||||||
Currency
translation
|
0.3 | — | — | — | 0.3 | |||||||||||
|
||||||||||||||||
Balance
At April 3, 2010
|
$ | 2.4 | $ | — | $ | 1.2 | $ | — | $ | 3.6 |
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
|
Three
Months Ended
|
||||||||||||
|
April
3,
|
March
28,
|
|||||||||||
(Dollars
in millions)
|
2010
|
2009
|
|||||||||||
|
|
|
|
|
|||||||||
Revenues
|
|
|
|
|
|||||||||
Analytical
Technologies
|
$ | 1,107.0 | 41.4% | $ | 938.8 | 41.6% | |||||||
Laboratory
Products and Services
|
1,695.2 | 63.4% | 1,423.0 | 63.1% | |||||||||
Eliminations
|
(127.1 | ) | (4.8)% | (106.7 | ) | (4.7)% | |||||||
|
|||||||||||||
|
$ | 2,675.1 | 100% | $ | 2,255.1 | 100% |
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of Operations –
Overview of Results of Operations and Liquidity
(continued)
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
(continued)
|
|
Three
Months Ended
|
|
|
|
|
||||||||||||||
|
April
3,
|
March
28,
|
Total
|
Currency
|
Acquisitions/
|
|
|||||||||||||
(In
millions)
|
2010
|
2009
|
Change
|
Translation
|
Divestitures
|
Operations
|
|||||||||||||
|
|
|
|
|
|
|
|||||||||||||
Revenues
|
|
|
|
|
|
|
|||||||||||||
Analytical
Technologies
|
$ | 1,107.0 | $ | 938.8 | $ | 168.2 | $ | 30.0 | $ | 46.9 | $ | 91.3 | |||||||
Laboratory
Products and
Services
|
1,695.2 | 1,423.0 | 272.2 | 36.3 | 25.3 | 210.6 | |||||||||||||
Eliminations
|
(127.1 | ) | (106.7 | ) | (20.4 | ) | (1.7 | ) | — | (18.7 | ) | ||||||||
|
|||||||||||||||||||
Consolidated
Revenues
|
$ | 2,675.1 | $ | 2,255.1 | $ | 420.0 | $ | 64.6 | $ | 72.2 | $ | 283.2 |
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of Operations –
Results of Operations (continued)
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of Operations –
Results of Operations (continued)
|
|
Three
Months Ended
|
||||||||
|
April
3,
|
March
28,
|
|
||||||
(Dollars
in millions)
|
2010
|
2009
|
Change
|
||||||
|
|
|
|
||||||
Revenues
|
|
|
|
||||||
Analytical
Technologies
|
$ | 1,107.0 | $ | 938.8 | 18% | ||||
Laboratory
Products and Services
|
1,695.2 | 1,423.0 | 19% | ||||||
Eliminations
|
(127.1 | ) | (106.7 | ) | 19% | ||||
|
|||||||||
Consolidated
Revenues
|
$ | 2,675.1 | $ | 2,255.1 | 19% | ||||
|
|||||||||
Segment
Income
|
|||||||||
Analytical
Technologies
|
$ | 232.4 | $ | 173.5 | 34% | ||||
Laboratory
Products and Services
|
235.3 | 175.5 | 34% | ||||||
|
|||||||||
Subtotal
Reportable Segments
|
467.7 | 349.0 | 34% | ||||||
|
|||||||||
Cost
of Revenues Charges
|
(5.1 | ) | — | ||||||
Selling,
General and Administrative Charges, Net
|
(1.1 | ) | — | ||||||
Restructuring
and Other Costs, Net
|
(17.4 | ) | (13.6 | ) | |||||
Amortization
of Acquisition-related Intangible Assets
|
(151.1 | ) | (145.3 | ) | |||||
|
|||||||||
Consolidated
Operating Income
|
$ | 293.0 | $ | 190.1 | 54% |
Three Months Ended | |||||||||
(Dollars in millions) |
April
3,
2010
|
March
28,
2009
|
Change | ||||||
|
|
|
|
||||||
Revenues
|
$ | 1,107.0 | $ | 938.8 | 18% | ||||
|
|||||||||
Operating
Income Margin
|
21.0% | 18.5% | 2.5 |
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of Operations –
Results of Operations (continued)
|
Three Months Ended | |||||||||
(Dollars
in millions)
|
April
3,
2010
|
March
28,
2009
|
Change | ||||||
|
|
|
|
||||||
Revenues
|
$ | 1,695.2 | $ | 1,423.0 | 19% | ||||
|
|||||||||
Operating
Income Margin
|
13.9% | 12.3% | 1.6 |
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of Operations –
Results of Operations (continued)
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
(continued)
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of Operations –
Liquidity and Capital
Resources (continued)
|
Item
3.
|
Quantitative
and Qualitative Disclosures About Market
Risk
|
Item
4.
|
Controls
and Procedures
|
Item
1A.
|
Risk
Factors
|
|
•
|
finding
new markets for our products;
|
|
•
|
developing
new applications for our
technologies;
|
|
•
|
combining
sales and marketing operations in appropriate markets to compete more
effectively;
|
|
•
|
allocating
research and development funding to products with higher growth
prospects;
|
|
•
|
continuing
key customer initiatives;
|
|
•
|
expanding
our service offerings;
|
|
•
|
strengthening
our presence in selected geographic markets;
and
|
|
•
|
continuing
the development of commercial tools and infrastructure to increase and
support cross-selling opportunities of products and services to take
advantage of our breadth in product
offerings.
|
Item
1A.
|
Risk
Factors (continued)
|
|
•
|
reduced
demand for some of our products;
|
|
•
|
increased
rate of order cancellations or
delays;
|
|
•
|
increased
risk of excess and obsolete
inventories;
|
|
•
|
increased
pressure on the prices for our products and services;
and
|
|
•
|
greater
difficulty in collecting accounts
receivable.
|
Item
1A.
|
Risk
Factors (continued)
|
Item
1A.
|
Risk
Factors (continued)
|
Item
1A.
|
Risk
Factors (continued)
|
Item
1A.
|
Risk
Factors (continued)
|
Item
1A.
|
Risk
Factors (continued)
|
Item
6.
|
Exhibits
|
THERMO
FISHER SCIENTIFIC INC.
|
|
/s/
Peter M. Wilver
|
|
Peter
M. Wilver
|
|
Senior
Vice President and Chief Financial Officer
|
|
/s/
Peter E. Hornstra
|
|
Peter
E. Hornstra
|
|
Vice
President and Chief Accounting
Officer
|
Exhibit
Number
|
Description
of Exhibit
|
||
10.1
|
Summary
of Annual Non-Management Director Compensation.*
|
||
10.2
|
Form
of Thermo Fisher Scientific Inc.’s March 2010 Restricted Stock Unit
Agreement (filed as Exhibit 10.1 to the Registrant’s Current Report on
Form 8-K filed March 10, 2010 [File No. 1-8002] and incorporated in this
document by reference).*
|
||
10.3
|
Form
of Thermo Fisher Scientific Inc.’s March 2010 Performance Restricted Stock
Unit Agreement (filed as Exhibit 10.2 to the Registrant’s Current Report
on Form 8-K filed March 10, 2010 [File No. 1-8002] and incorporated in
this document by reference).*
|
||
31.1 | Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||
31.2
|
Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||
32.1 |
Certification
of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and
15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.**
|
||
32.2 |
Certification
of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and
15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.**
|
||
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries. | |||
101.INS |
XBRL
Instance Document.
|
||
101.SCH |
XBRL
Taxonomy Extension Schema Document.
|
||
101.CAL |
XBRL
Taxonomy Calculation Linkbase Document.
|
||
101.LAB |
XBRL
Taxonomy Label Linkbase Document.
|
||
101.PRE |
XBRL
Taxonomy Presentation Linkbase
Document.
|
*Indicates
management contract or compensatory plan, contract or
arrangement.
|
|
**Certification
is not deemed “filed” for purposes of Section 18 of the Exchange Act or
otherwise subject to the liability of that section. Such
certification is not deemed to be
incorporated by reference into any
filing under the Securities Act or the Exchange Act except to the extent
that the registrant specifically incorporates it by
reference.
|